Az antiösztrogén hatású 4-kloro-1,2-difenil-1-(4-[2-(N,N-dimetilamino)etoxi]fenil)-1-butén (Toremifene) hatása emlörákos betegek endokrin regulációjára.

Translated title of the contribution: The anti-estrogenic effect of 4-chloro-1,2-diphenyl-1-(4-[2-(N,N-dimethylamino)ethoxy]phenyl)1-butene (Toremifene) on the endocrine regulation in breast cancer patients

I. Számel, I. Hindy, B. Vincze, N. Ady, S. Eckhardt

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In a combined phase I-II study the hormonal effects of Toremifene were investigated in 15-15 patients at two dose levels: 60 mg and 300 mg per os, daily. Serum estradiol, progesterone, testosterone, follicle-stimulating hormone, luteinizing hormone, prolactin, human growth hormone were monitored by radioimmunoassay and sexual hormone binding globulin by immunoradiometric assay prior to treatment and at the 2nd, 8th and 12th weeks. The influence of Toremifene upon the hypothalamo-hypophyseal axis was also controlled by a tirotropin releasing hormone functional test using 400 micrograms tirotropin releasing hormone injection iv. Estradiol, progesterone, follicle-stimulating hormone, luteinizing hormone and prolactin decreased proving the antiestrogenic activity of the drug. Sexual hormone binding globulin significantly (p less than 0.002) increased by week 12 at both doses, probably due to a direct effect of Toremifene upon the liver. The increase in sexual hormone binding globulin suggests the partial estrogenic effect of the drug. The tirotropin releasing hormone induced prolactin release was also suppressed. On the basis of hormonal changes and the clinical response of patients 60 mg of Toremifene proved to be as effective as 300 mg.

Original languageHungarian
Pages (from-to)683-686
Number of pages4
JournalOrvosi Hetilap
Volume132
Issue number13
Publication statusPublished - Mar 31 1991

Fingerprint

Toremifene
Estrogens
Hormones
Breast Neoplasms
Globulins
Follicle Stimulating Hormone
Luteinizing Hormone
Prolactin
Progesterone
Estradiol
Prolactin-Releasing Hormone
Immunoradiometric Assay
Human Growth Hormone
Pharmaceutical Preparations
Radioimmunoassay
Testosterone
1-butene
diphenyl
Injections
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az antiösztrogén hatású 4-kloro-1,2-difenil-1-(4-[2-(N,N-dimetilamino)etoxi]fenil)-1-butén (Toremifene) hatása emlörákos betegek endokrin regulációjára. / Számel, I.; Hindy, I.; Vincze, B.; Ady, N.; Eckhardt, S.

In: Orvosi Hetilap, Vol. 132, No. 13, 31.03.1991, p. 683-686.

Research output: Contribution to journalArticle

@article{05a41c9e605549f0bd8406fee4068bda,
title = "Az anti{\"o}sztrog{\'e}n hat{\'a}s{\'u} 4-kloro-1,2-difenil-1-(4-[2-(N,N-dimetilamino)etoxi]fenil)-1-but{\'e}n (Toremifene) hat{\'a}sa eml{\"o}r{\'a}kos betegek endokrin regul{\'a}ci{\'o}j{\'a}ra.",
abstract = "In a combined phase I-II study the hormonal effects of Toremifene were investigated in 15-15 patients at two dose levels: 60 mg and 300 mg per os, daily. Serum estradiol, progesterone, testosterone, follicle-stimulating hormone, luteinizing hormone, prolactin, human growth hormone were monitored by radioimmunoassay and sexual hormone binding globulin by immunoradiometric assay prior to treatment and at the 2nd, 8th and 12th weeks. The influence of Toremifene upon the hypothalamo-hypophyseal axis was also controlled by a tirotropin releasing hormone functional test using 400 micrograms tirotropin releasing hormone injection iv. Estradiol, progesterone, follicle-stimulating hormone, luteinizing hormone and prolactin decreased proving the antiestrogenic activity of the drug. Sexual hormone binding globulin significantly (p less than 0.002) increased by week 12 at both doses, probably due to a direct effect of Toremifene upon the liver. The increase in sexual hormone binding globulin suggests the partial estrogenic effect of the drug. The tirotropin releasing hormone induced prolactin release was also suppressed. On the basis of hormonal changes and the clinical response of patients 60 mg of Toremifene proved to be as effective as 300 mg.",
author = "I. Sz{\'a}mel and I. Hindy and B. Vincze and N. Ady and S. Eckhardt",
year = "1991",
month = "3",
day = "31",
language = "Hungarian",
volume = "132",
pages = "683--686",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "13",

}

TY - JOUR

T1 - Az antiösztrogén hatású 4-kloro-1,2-difenil-1-(4-[2-(N,N-dimetilamino)etoxi]fenil)-1-butén (Toremifene) hatása emlörákos betegek endokrin regulációjára.

AU - Számel, I.

AU - Hindy, I.

AU - Vincze, B.

AU - Ady, N.

AU - Eckhardt, S.

PY - 1991/3/31

Y1 - 1991/3/31

N2 - In a combined phase I-II study the hormonal effects of Toremifene were investigated in 15-15 patients at two dose levels: 60 mg and 300 mg per os, daily. Serum estradiol, progesterone, testosterone, follicle-stimulating hormone, luteinizing hormone, prolactin, human growth hormone were monitored by radioimmunoassay and sexual hormone binding globulin by immunoradiometric assay prior to treatment and at the 2nd, 8th and 12th weeks. The influence of Toremifene upon the hypothalamo-hypophyseal axis was also controlled by a tirotropin releasing hormone functional test using 400 micrograms tirotropin releasing hormone injection iv. Estradiol, progesterone, follicle-stimulating hormone, luteinizing hormone and prolactin decreased proving the antiestrogenic activity of the drug. Sexual hormone binding globulin significantly (p less than 0.002) increased by week 12 at both doses, probably due to a direct effect of Toremifene upon the liver. The increase in sexual hormone binding globulin suggests the partial estrogenic effect of the drug. The tirotropin releasing hormone induced prolactin release was also suppressed. On the basis of hormonal changes and the clinical response of patients 60 mg of Toremifene proved to be as effective as 300 mg.

AB - In a combined phase I-II study the hormonal effects of Toremifene were investigated in 15-15 patients at two dose levels: 60 mg and 300 mg per os, daily. Serum estradiol, progesterone, testosterone, follicle-stimulating hormone, luteinizing hormone, prolactin, human growth hormone were monitored by radioimmunoassay and sexual hormone binding globulin by immunoradiometric assay prior to treatment and at the 2nd, 8th and 12th weeks. The influence of Toremifene upon the hypothalamo-hypophyseal axis was also controlled by a tirotropin releasing hormone functional test using 400 micrograms tirotropin releasing hormone injection iv. Estradiol, progesterone, follicle-stimulating hormone, luteinizing hormone and prolactin decreased proving the antiestrogenic activity of the drug. Sexual hormone binding globulin significantly (p less than 0.002) increased by week 12 at both doses, probably due to a direct effect of Toremifene upon the liver. The increase in sexual hormone binding globulin suggests the partial estrogenic effect of the drug. The tirotropin releasing hormone induced prolactin release was also suppressed. On the basis of hormonal changes and the clinical response of patients 60 mg of Toremifene proved to be as effective as 300 mg.

UR - http://www.scopus.com/inward/record.url?scp=0026434523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026434523&partnerID=8YFLogxK

M3 - Article

C2 - 1826556

AN - SCOPUS:0026434523

VL - 132

SP - 683

EP - 686

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 13

ER -